These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25810013)

  • 1. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
    Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
    PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
    Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown.
    Previdi S; Abbadessa G; Dalò F; France DS; Broggini M
    Mol Cancer Ther; 2012 Jan; 11(1):214-23. PubMed ID: 22027690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
    Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
    Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
    Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
    Baljevic M; Zaman S; Baladandayuthapani V; Lin YH; de Partovi CM; Berkova Z; Amini B; Thomas SK; Shah JJ; Weber DM; Fu M; Cleeland CS; Wang XS; Stellrecht CM; Davis RE; Gandhi V; Orlowski RZ
    Ann Hematol; 2017 Jun; 96(6):977-985. PubMed ID: 28337527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
    Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
    Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification.
    Kim BJ; Kim YJ; Sohn SH; Kim B; Sul HJ; Kim HS; Zang DY
    Invest New Drugs; 2020 Dec; 38(6):1633-1640. PubMed ID: 32361789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.
    Phillip CJ; Zaman S; Shentu S; Balakrishnan K; Zhang J; Baladandayuthapani V; Taverna P; Redkar S; Wang M; Stellrecht CM; Gandhi V
    J Hematol Oncol; 2013 Dec; 6():92. PubMed ID: 24326130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
    Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
    Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
    Lu S; Török HP; Gallmeier E; Kolligs FT; Rizzani A; Arena S; Göke B; Gerbes AL; De Toni EN
    Oncotarget; 2015 Sep; 6(26):22167-78. PubMed ID: 26259250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
    Xi WH; Yang LY; Cao ZY; Qian Y
    Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.